Benitec Biopharma (BNTC) Competitors $10.68 +0.28 (+2.69%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends BNTC vs. ORGO, VALN, AMLX, FDMT, CCCC, AKBA, CGC, CYRX, VYGR, and SAGEShould you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Organogenesis (ORGO), Valneva (VALN), Amylyx Pharmaceuticals (AMLX), 4D Molecular Therapeutics (FDMT), C4 Therapeutics (CCCC), Akebia Therapeutics (AKBA), Canopy Growth (CGC), Cryoport (CYRX), Voyager Therapeutics (VYGR), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry. Benitec Biopharma vs. Organogenesis Valneva Amylyx Pharmaceuticals 4D Molecular Therapeutics C4 Therapeutics Akebia Therapeutics Canopy Growth Cryoport Voyager Therapeutics Sage Therapeutics Organogenesis (NASDAQ:ORGO) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk. Does the MarketBeat Community favor ORGO or BNTC? Benitec Biopharma received 92 more outperform votes than Organogenesis when rated by MarketBeat users. However, 66.44% of users gave Organogenesis an outperform vote while only 64.73% of users gave Benitec Biopharma an outperform vote. CompanyUnderperformOutperformOrganogenesisOutperform Votes9766.44% Underperform Votes4933.56% Benitec BiopharmaOutperform Votes18964.73% Underperform Votes10335.27% Which has more volatility and risk, ORGO or BNTC? Organogenesis has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Is ORGO or BNTC more profitable? Benitec Biopharma has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Organogenesis' return on equity of -2.69% beat Benitec Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-1.62% -2.69% -1.63% Benitec Biopharma N/A -90.14%-75.25% Which has preferable valuation and earnings, ORGO or BNTC? Organogenesis has higher revenue and earnings than Benitec Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$433.14M1.19$4.95M-$0.06-64.67Benitec Biopharma$80K1,408.44-$21.75MN/AN/A Do institutionals and insiders hold more shares of ORGO or BNTC? 49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 36.9% of Organogenesis shares are owned by insiders. Comparatively, 1.3% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to ORGO or BNTC? In the previous week, Organogenesis had 11 more articles in the media than Benitec Biopharma. MarketBeat recorded 18 mentions for Organogenesis and 7 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.87 beat Organogenesis' score of 0.65 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 4 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Benitec Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ORGO or BNTC? Organogenesis presently has a consensus target price of $5.33, suggesting a potential upside of 37.46%. Benitec Biopharma has a consensus target price of $22.60, suggesting a potential upside of 111.81%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Benitec Biopharma is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryBenitec Biopharma beats Organogenesis on 9 of the 17 factors compared between the two stocks. Ad Genesis Gold GroupTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNTC vs. The Competition Export to ExcelMetricBenitec BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.68M$6.51B$5.06B$8.70BDividend YieldN/A8.04%4.97%4.05%P/E RatioN/A6.99106.6415.04Price / Sales1,408.44380.301,278.0086.84Price / CashN/A53.5139.6136.41Price / Book2.289.426.345.90Net Income-$21.75M$154.14M$118.56M$225.31M7 Day Performance0.85%-5.80%-3.21%-1.81%1 Month Performance8.77%-0.44%0.18%2.80%1 Year Performance183.02%31.91%32.59%23.94% Benitec Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNTCBenitec Biopharma2.3024 of 5 stars$10.68+2.7%$22.60+111.6%+187.3%$112.78M$80,000.000.0020Short Interest ↑News CoverageORGOOrganogenesis4.2039 of 5 stars$3.28+0.6%N/A+58.9%$434.85M$448.39M-25.23950Earnings ReportNews CoverageGap UpVALNValneva2.8396 of 5 stars$5.24-4.4%N/A-62.6%$425.75M$165.52M-10.08700Gap DownHigh Trading VolumeAMLXAmylyx Pharmaceuticals3.3478 of 5 stars$6.70+2.4%N/A-59.9%$423.47M$380.79M-2.73200Short Interest ↑FDMT4D Molecular Therapeutics3.0342 of 5 stars$8.12-1.9%N/A-27.7%$422.00M$20.72M-3.53201Analyst ForecastShort Interest ↓News CoveragePositive NewsGap DownCCCCC4 Therapeutics2.1357 of 5 stars$6.06+0.3%N/A+156.5%$421.42M$20.76M-3.56150Short Interest ↓AKBAAkebia Therapeutics3.9643 of 5 stars$1.94+3.7%N/A+80.6%$420.58M$194.62M-9.24167CGCCanopy Growth1.9663 of 5 stars$4.24-6.8%N/A-29.6%$397.97M$220.27M-0.601,029Short Interest ↓Analyst RevisionCYRXCryoport2.8802 of 5 stars$7.73-3.6%N/A-43.8%$396.29M$233.26M-2.111,170Gap UpVYGRVoyager Therapeutics4.531 of 5 stars$7.13+0.4%N/A-8.1%$388.82M$250.01M25.46100Analyst ForecastAnalyst RevisionNews CoverageSAGESage Therapeutics4.4601 of 5 stars$6.31-0.2%N/A-72.2%$386.00M$106.40M-1.13690 Related Companies and Tools Related Companies ORGO Alternatives VALN Alternatives AMLX Alternatives FDMT Alternatives CCCC Alternatives AKBA Alternatives CGC Alternatives CYRX Alternatives VYGR Alternatives SAGE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BNTC) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
